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Apoptosisa b s t r a c t
Oncogenic activation of VEGF is found in various malignancies, including ovarian cancer. In this
study, we investigate the role of microRNA (miRNA) in the regulation of VEGF in ovarian cancer.
We ﬁnd that miR-718 is expressed at low levels and inversely correlates with VEGF expression in
ovarian cancer specimens. MiR-718 also directly targets and represses VEGF expression. In addition,
miR-718 restoration inhibits ovarian cancer proliferation both in vitro and in vivo. Moreover, VEGF
expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phos-
phorylated AKT. These results suggest a new therapeutic strategy in ovarian cancer by restoring
miR-718 expression, which is involved in VEGF regulation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ovarian cancer is a deadly malignancy in women [12]. Given the
few early symptoms of ovarian cancer, the majority of the patients
are diagnosed at an advanced stage, which has a ﬁve-year survival
rate of only 20–25% [1,4]. Although the current standard treatment
combining surgery with chemotherapy is efﬁcient, the ﬁve-year
survival rate is also low because of the high recurrence rate and
drug resistance [10,22]. Therefore, innovative and reliable diagnos-
tic or prognostic biomarkers and more efﬁcient therapeutic meth-
ods are urgently needed to treat ovarian cancer.
MicroRNAs (miRNAs) are small non-coding RNAs (21–23 nt)
that regulate gene expression through translational repression
and mRNA degradation. MiRNAs are involved in various biological
processes, including embryonic development, viral infections, and
cancer development. Increasing body of evidence has demon-
strated the altered expression of miRNAs in ovarian cancer, thereby
suggesting that miRNA could be involved in the regulation of ovar-
ian cancer. For example, miR-214 regulates ovarian cancer stem
cell properties by targeting p53/Nanog and induces cell survival
and cisplatin resistance by targeting PTEN in ovarian cancer cells
[26,27]. In addition, the deregulation of miR-15a, miR-16, miR-
20a, and miR-125b was also detected in ovarian cancer [1,6,9].
Although more than 1000 miRNAs have been identiﬁed and someof them are well studied, the function of miR-718 in human can-
cers is unclear.
Vascular endothelial growth factor (VEGF) A is a glycosylated
mitogen that is widely expressed in endothelial cells and has var-
ious effects, including angiogenesis, stem cell implantation, cancer
cell proliferation, and migration [3,5,17,19,28]. The present study
aims to investigate the therapeutic effect of VEGF and its miRNA
regulation in ovarian cancer. In this study, detailed molecular
mechanism was discussed, focusing on the effect of miR-718 on
VEGF. These results are helpful for deeper understanding of the
anti-cancer mechanism of miRNA.2. Materials and methods
2.1. Cell lines and human tissues
ES-2 SKOV-3 and Caov-3 were purchased from the Chinese
Academy of Sciences Type Culture Collection (Shanghai, China).
OVCAR-3 was purchased from American Type Culture Collection
(ATCC) (Washington, DC, USA). ES-2 SKOV-3 and OVCAR-3 were
grown in RPMI 1640 containing 10% fetal bovine serum (FBS),
and Caov-3 was grown in DMEM (Gibco, Grand Island, NY) contain-
ing 10% FBS. They were all cultured at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2. Human ovarian cancer specimens
(n = 20) and paired adjacent specimens (n = 20) were obtained
from the patients at The First Afﬁliated Hospital of Chongqing
Medical University with documented individual informed consent.
Fig. 1. Low miR-718 expression is inversely correlated with VEGF expression in ovarian cancer. (A) RNA was collected from paired ovarian cancer specimens and cell lines
were used to measure miR-718 expression. The comparative Ct method was used to calculate the relative abundance of miR-718 with respect to U6. The miR-718 expression
in normal ovarian tissues was set to 1. (B) VEGF expression in these specimens and cell lines were also analyzed using qRT-PCR. GAPDH was used as loading control. (C)
Western blot was performed to analyze the VEGF protein, and GAPDH was used as control. (D and E) The correlation between miR-718/VEGF mRNA and miR-718/VEGF
protein were analyzed using GraphPad Software. ⁄P < 0.05.
R. Leng et al. / FEBS Letters 588 (2014) 2078–2086 2079
2080 R. Leng et al. / FEBS Letters 588 (2014) 2078–2086Patients undergoing surgery for ovarian cancer provided the writ-
ten consent to donate tissue for analysis. All the specimens infor-
mation are listed in Table S1.
2.2. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from transfected cells and tissues using
TRIzol reagent (Invitrogen). For quantiﬁcation of mature miRNA
levels, RNA was ﬁrst reverse-transcribed with miRNA-speciﬁc
primers using TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems) and qRT-PCR was performed using a Tapman
microRNA assay kit (ABI). U6 snRNA was used as control. To detect
the VEGF level, 5 lg of the fraction of large RNA was used in the
reverse transcription. VEGF gene (270 bp) was ampliﬁed with spe-
ciﬁcally paired primers (forward, 50-GGGCAAAGTGAGTGACCTG-30,
and reverse, 50-CAGCCCAGAAGTTGGACGA-30), and GAPDH was
used as the loading control. The miR-718 and VEGF expression lev-
els and were quantiﬁed using the 2DDCt method. Each experiment
was performed in triplicate.
2.3. siRNA and DNA construction
To construct miR-718 expression plasmid, the DNA fragment
containing miR-718 sequence was ampliﬁed from HeLa cell gen-
ome using speciﬁc primers (miR-718-F 50-CGCGGATCCTCTGTCCC
CAACGCCGGGA-30 and miR-718-R 50-CCGGAATTCTCCGCGGAC
ACTGACTCAC-30). The PCR products were then inserted into the
pcDNA3.1 with the use of BamHI and EcoRI. The DNA fragments
of wild VEGF 30UTR and mutated VEGF 30UTR were synthesized
(Genewize, China) and then inserted into pmirGLO dual-luciferase
reporter vector (Promega, Madison, WI, USA) with the use of NheI
and SalI, separately. DNA fragment containing VEGF coding
sequences was ampliﬁed from the HeLa cell cDNA library using
paired primers (CDS-F and CDS-R) and inserted into the pCMV-
myc expression plasmid with the use of EcoRI and XhoI. The primer
sequences are as follows: CDS-F, 50-CCGGAATTCCTGACGGACAGAFig. 2. MiR-718 directly represses VEGF expression in ovarian cancer cells. (A) Bioin
TargetScan database. (B and C) VEGF expression in miR-718-overexpressing ES-2 cells w
GAPDH. (D) Wild and mutated luciferase reporter plasmids were transfected alone or c
After 48 h, the cells were lysed, and then the normalized ﬁreﬂy luciferase activity (ﬁreﬂCAGACAG-30; CDS-R, 50-CCGCTCGAGTCACCGCCTCGGCTTGTCA-30.
The siRNA sequences were the following: VEGF siRNA, 50-AUGU-
GAAUGCAGACCAAAGAA-TT; Ctrl siRNA, 50-GAUAGCAA UGACGA-
AUGCGUA-TT.
2.4. MK2206 treatment
Ovarian cancer cells were plated at six well plate, 24 h after
transfection with miR-718 and VEGF expression vector. MK2206
was added to the medium at a concentration of 2 lM and grown
at 37 C for 24 h.
2.5. Cell viability assay
Cells (103) were seeded in 96-well plate and maintained at
37 C for 24, 48, and 72 h after transfection. The cells were then
treated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide. After 4 h, the absorbance at 570 nm was determined with
the use of a microplate reader.
2.6. Cell invasion assay
Cell invasive ability was measured in Transwell chambers
coated with Matrigel (8 lm pore; BD Biosciences, Franklin Lakes,
NJ). Tumor cells were seeded in the upper chamber with RPMI-
1640 containing 2% FBS at a ﬁnal concentration of 1  105 cells
per well. The bottom chamber was ﬁlled with RPMI-1640 contain-
ing 10% FBS. After 16 h, the cells that invaded the underside of the
polycarbonate membrane were stained with crystal violet and
photographed under a microscope.
2.7. Flow cytometry analysis
Tumor cells were seeded in six-well plate (Corning, USA).
Approximately 48 h after transfection, the cells were washed
with cold PBS. Annexin V-PE/7-AAD apoptosis detection kit (BDformatics prediction results of miR-718 binding sequence in VEGF mRNA using
as evaluated by PCR (B) and Western blot (C). Normalization was performed with
otransfected with miR-718 expression vector or control vectors into the ES-2 cells.
y luciferase activity/renilla luciferase activity) was calculated. ⁄P < 0.05.
Fig. 3. Effect of miR-718 expression on ovarian cancer cell lines. SKOV-3 and ES-2 ovarian cancer cells were transfected with miR-718 expression vector or control vector.
After 48 h, the cells were collected for analysis. (A) The miR-718 expression in transfected SKOV-3 and ES-2 cells was analyzed using qRT-PCR. (B) MTT assay was performed
to analyze cell viability at 24, 48, and 72 h after transfection. (C–E) Cell invasive ability (C and D) and apoptosis (E) of the two treated cell lines were analyzed by transwell and
ﬂow cytometry analysis. (F and G) The effect of miR-718 on ovarian cancer cell proliferation was analyzed by colony formation assay. ⁄P < 0.05.
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accordance with the manufacturer’s instruction. The cells were
then analyzed using ﬂow cytometry.
2.8. Luciferase reporter assays
Tumor cells were seeded in 96-well plates and grown in RPMI
1640 containing 10% FBS at 37 C in a humidiﬁed atmosphere con-
taining 5% CO2. After 24 h, luciferase reporter plasmids were trans-
fected separately or cotransfected with miR-718 expression
plasmid or pcDNA3.1. Fireﬂy and renilla luciferase activities were
measured at 48 h after transfection using the Dual-Glo Luciferase
Assay System (Promega, USA). Fireﬂy luciferase was normalized to
renilla luciferase activity.Fig. 4. Knockdown of VEGF inhibits ovarian cancer cell progression. (A) VEGF siRNA and
level was analyzed by Western blot, GAPDH was used as loading control. (B) MTT assay
invasive ability (C) and apoptosis (D) were analyzed by transwell and ﬂow cytometry a2.9. Western blot
Tumor tissues and cells were washed with PBS and lysed in ice-
cold lysis buffer with Protease Inhibitor Cocktail (Sigma) or Phos-
phatase Inhibitor Cocktail 3 (Sigma) on ice for 30 min. Lysates were
separated by electrophoresis and transferred onto polyvinylidene
diﬂuoride membranes (Millipore, Bedford, MA, USA). The mem-
branes were blocked and incubated with primary antibody of VEGF
(Abcam, Cambridge, UK), AKT (Cell signaling, USA), and p-AKT (Cell
signaling, USA). They were then incubated with a goat anti-rabbit
IgG-HRP secondary antibody (sc-2004, Santa Cruz, CA, USA). GAP-
DH was used as loading control. Protein expression was assessed
by enhanced chemiluminescence and exposure to the chemilumi-
nescent ﬁlm.Ctrl siRNA were transfected into ES-2 and SKOV-3 cells. 48 h later, the VEGF protein
was performed to analyze cell viability at 24, 48, and 72 h after transfection. Cell
ssay. ⁄P < 0.05.
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BABL/c nude mice purchased from the Animal Center of Chinese
Academy of Science (Shanghai, China) were randomly assigned
into four groups (eight mice per group). A total of 1  107 SKOV-
3 and ES-2 cells stably expressing miR-718 were injected subcuta-
neously into nude mice. Cells transfected with control vector were
used as the control group. The mice were sacriﬁced 19 d after injec-
tion. Tumor volume was evaluated using the following equation:
tumor formula = 4p/3  (width/2)2  (length/2).
2.11. Statistical analysis
All data in the study were evaluated using SPSS 11.5 (SPSS Inc.,
USA). Student0s t-test or one-way ANOVA test was performed to
analyze the signiﬁcance of differences between sample means
obtained from three independent experiments. A value of
P < 0.05 was considered signiﬁcant.
3. Results
3.1. Negative correlation between miR-718 and VEGF expression in
ovarian cancer specimens and cell lines
Bioinformatics analyses suggested the presence of miR-718
binding site on the 30UTR of human VEGF mRNAs. Therefore, we
performed qRT-PCR and Western blot to analyze the expression
levels of miR-718, as well as the VEGF mRNA/proteins and miRNAs,Fig. 5. Restoration of VEGF prevents the inhibition of cell phenotype by miR-718 in ovar
ovarian cancer cells, which were treated with miR-718 expression vector. After 48 h, th
Western blot. (B) Flow cytometry analysis was performed to evaluate cell apoptosis in V
invasive ability were analyzed using Transwell assay. ⁄P < 0.05.in the ovarian cancer and control tissues. Compared with the
expression levels in the normal tissues, VEGF mRNA/proteins were
highly expressed in ovarian cancer tissues, whereas miR-718 was
downregulated (Fig. 1A–C). Moreover, we found that the expres-
sion of miR-718 was inversely correlated with mRNA and protein
expression of VEGF in ovarian cancer specimens (Fig. 1D and E)
3.2. MiR-718 directly represses VEGF by binding its 30UTR
To conﬁrm the correlation between miR-718 and VEGF, Target-
Scan database was used to ﬁnd the binding sequence of miR-718 in
VEGF mRNA (205–212 of VEGF 30UTR) (Fig. 2A). qRT-PCR, Western
blot and luciferase activity assays were performed to determine
whether miR-718 could directly repress VEGF expression. qRT-
PCR and Western blot results showed that the VEGF expression
level was lower in miR-718-overexpressing ES-2 cells than that
in control group (Fig. 2B and C). Luciferase activity was repressed
by miR-718 in the wild VEGF 30UTR group, but not in the VEGF
30UTR with mutated miR-718 binding sequence (Fig. 2D).
3.3. MiR-718 overexpression inhibits cell proliferation and promotes
apoptosis in ovarian cancer cells
Given that miR-718 was lowly expressed in ovarian cancer tis-
sues and cell lines, we hypothesized that miR-718 may act as
tumor suppressor in ovarian cancer development. In this study,
we transfected miR-718 expression plasmid into ES-2 and SKOV-
3 cells, and pcDNA3.1 was used as control. Compared with theian cancer cells. (A) VEGF expression plasmid or control vector was transfected into
e expression of VEGF, AKT, and p-AKT (ser473) in ES-2 cells were determined by
EGF-restored ovarian cancer cells, ES-2 and SKOV-3. (C) The effects of VEGF on cell
Fig. 6. In vivo anti-ovarian cancer effect of miR-718. (A and B) After the mice were sacriﬁced, the mice and tumors were photographed (A), the tumor volume is shown in B. (C
and D) These solid tumors were collected and lysed to analyze the miR-718 and VEGF expression. (C) The miR-718 expression in these tumors was analyzed using qRT-PCR;
U6 snRNA was used as control. (D) Western blot was performed to detect the VEGF protein level in these tissues; GAPDH was used as control. ⁄P < 0.05.
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cantly upregulated miR-718 expression in ES-2 and SKOV-3
(Fig. 3A). In cell MTT analysis, miR-718 overexpression inhibited
the cellular viability (Fig. 3B). In addition, miR-718 overexpression
in ovarian cancer cells promoted cell apoptosis and inhibited cell
invasive ability (Fig. 3C–E). Furthermore, the effect of miR-718
on cell colony formation ability was analyzed (Fig. 3F and G).
3.4. Knockdown of VEGF by siRNA inhibits ovarian cancer cell
proliferation
From the above results, we found that miR-718 directly tar-
gets VEGF and inhibits ovarian cancer cell proliferation. If this
effect of miR-718 on ovarian cancer is mediated by VEGF, knock-
down of VEGF should have similar role to miR-718 overexpres-
sion. Here we used VEGF speciﬁc siRNA to suppress VEGF
expression. As shown in Fig. 4A, VEGF siRNA strongly decreased
VEGF expression in ES-2 and SKOV-3 cells. MTT and transwell
assay revealed that knockdown of VEGF inhibited ovarian cancer
cell viability and invasion (Fig. 4B and C). Results of ﬂow cytom-
etry analysis showed that knockdown of VEGF promoted cell
apoptosis of ovarian cancer cells compared with those in the con-
trol group (Fig. 4D). These results indicated that VEGF siRNA has
similar suppressive effect with miR-718 overexpression on ovar-
ian cancer cells.3.5. Restoration of VEGF expression resists the effect of miR-718
overexpression on ovarian cancer cells
To further conﬁrmed the suppression role of miR-718 in ovarian
cancer cells is mediated by VEGF, we transfected VEGF expression
plasmid into miR-718-overexpressing ovarian cancer cells to
determine whether VEGF restoration could reverse the effect of
miR-718 on ovarian cancer cells. As shown in Fig. 5A, transfection
of VEGF expression plasmid promoted the VEGF and p-AKT
(ser473) expression in miR-718-treated ovarian cancer cells com-
pared with those in the control group. Results of invasive ability
assay and ﬂow cytometry analysis showed that VEGF expression
promoted cell invasion and inhibited apoptosis of ovarian cancer
cells compared with those in the control group (Fig. 5B and C). This
phenomenon indicated that VEGF could reverse the effect on miR-
718 on ovarian cancer cells.
3.6. MiR-718 suppresses the ovarian tumor growth in vivo
MiR-718 was proved to downregulate ovarian cancer cell pro-
gression in vitro. To test whether miR-718 has similar function
on ovarian cancer in vivo, we established miR-718-expression sta-
ble ovarian cancer cell lines, and cells transfected with pcDNA3.1
were used as control. The cells were injected subcutaneously in
the armpit in all of mice, and tumor progression was recorded.
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tumors were removed and photographed. As shown in Fig. 6A
and B, tumor volume was smaller in miR-718-overexpression
groups than that in the control group. The results of qRT-PCR and
Western blot analysis showed that miR-718 expression was upreg-
ulated, whereas VEGF expression was signiﬁcantly downregulated
in miR-718-overexpression groups compared with that in the con-
trol groups.4. Discussion
MiRNAs are important regulators in human cancer and their
roles as therapeutic targets have been proposed. MiRNA deregula-
tion in ovarian cancer suggests that miRNAs are involved in the ini-
tiation and progression of this disease. In this study, we detected
low miR-718 expression and identiﬁed VEGF as an miR-718 target
in ovarian cancer.
VEGF is widely expressed in diverse human tumors, including
lung, breast, and colorectal cancers, and has been shown as a nota-
ble prognostic marker in ovarian, renal, esophageal, and bladder
cancers [11,13–15,24,25]. Increasing body of evidence has shown
the correlation between VEGF and miRNAs. For example, miR-
126 restoration downregulates VEGF and inhibits tumor growth
of lung cancer both in vitro and in vivo [16]. In hepatocellular car-
cinoma, ectopic miR-125a represses VEGF expression and inhibits
cancer cell proliferation and invasion [2]. In the present study,
we found high VEGF expression, which was regulated directly by
miR-718 in ovarian cancer.
The crucial role of VEGF in ovarian cancer has been well elab-
orated in earlier studies from the previous century. Upregulated
levels of VEGF have been reported in ovarian carcinoma com-
pared with benign tumors or healthy patients [7,20,21]. VEGF
repression has been shown to inhibit cell proliferation, migration,
and tumor growth in ovarian cancer [8,18,23]. In the present
study, the expression levels of VEGF mRNA and protein were
compared between normal and ovarian cancer tissues. The results
showed that the VEGF level was relatively higher in ovarian can-
cer tissues and inversely correlated with miR-718 expression.
Furthermore, the effect of miR-718 on the proliferation and inva-
sion of ovarian cancer was investigated in ES-2 and SKOV-3 cells.
Results showed that miR-718 overexpression could prevent the
proliferation and invasion of cancer cells. Given that individual
miRNA can regulate many genes, we used luciferase reporter
assay to conﬁrm whether VEGF is directly regulated by miR-
718. In addition, VEGF restoration promoted cell invasion and
inhibited apoptosis in miR-718-overexpressing ovarian cancer
cells. Therefore, miR-718 may be a potential therapeutic target
for the treatment of ovarian cancer with high VEGF level. This
therapeutic effect has been demonstrated in vivo in the present
study.
In conclusion, our results show that miR-718 exhibits inhibitory
effects against ovarian cancer through VEGF repression. This newly
identiﬁed miR-718/VEGF link provides a potential therapeutic tar-
get to treat ovarian cancer.5. Disclosure statement
The authors have no conﬂict of interest.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2014.04.
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